"Circulating Tumor DNA" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
DNA released from tumor cells that is found circulating in PLASMA; SERUM; or other BODY FLUIDS.
| Descriptor ID |
D000074141
|
| MeSH Number(s) |
D13.444.154.500 D13.444.308.425.500
|
| Concept/Terms |
Circulating Tumor DNA- Circulating Tumor DNA
- DNA, Circulating Tumor
- Tumor DNA, Circulating
- Cell-Free Tumor DNA
- Cell Free Tumor DNA
- DNA, Cell-Free Tumor
- Tumor DNA, Cell-Free
|
Below are MeSH descriptors whose meaning is more general than "Circulating Tumor DNA".
Below are MeSH descriptors whose meaning is more specific than "Circulating Tumor DNA".
This graph shows the total number of publications written about "Circulating Tumor DNA" by people in this website by year, and whether "Circulating Tumor DNA" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 3 | 0 | 3 |
| 2020 | 5 | 0 | 5 |
| 2021 | 2 | 0 | 2 |
| 2022 | 4 | 0 | 4 |
| 2023 | 5 | 0 | 5 |
| 2024 | 1 | 0 | 1 |
| 2025 | 4 | 1 | 5 |
| 2026 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Circulating Tumor DNA" by people in Profiles.
-
Translating ctDNA into cutaneous melanoma care: An international expert survey. Eur J Cancer. 2026 May 15; 239:116676.
-
ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer. Nat Commun. 2026 Mar 12; 17(1).
-
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease. J Clin Oncol. 2026 May 10; 44(14):1283-1295.
-
Detection of Cancers Three Years prior to Diagnosis Using Plasma Cell-Free DNA. Cancer Discov. 2025 Sep 04; 15(9):1794-1802.
-
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clin Lung Cancer. 2025 Nov; 26(7):e503-e513.e11.
-
Circulating tumor HPV DNA, antibodies to HPV16 early proteins, and oral HPV16 DNA as biomarkers for HPV-related oropharyngeal cancer screening. Cancer Biomark. 2025 Jan; 42(1):18758592241313323.
-
A deep-learning model for quantifying circulating tumour DNA from the density distribution of DNA-fragment lengths. Nat Biomed Eng. 2025 Mar; 9(3):307-319.
-
The Landscape of ctDNA in Appendiceal Adenocarcinoma. Clin Cancer Res. 2025 Feb 03; 31(3):551-560.
-
Circulating tumor DNA predicts venous thromboembolism in patients with cancers. J Thromb Haemost. 2025 Jan; 23(1):139-148.
-
Utility of Circulating Tumor DNA in Appendiceal Tumors. J Gastrointest Surg. 2023 12; 27(12):3071-3073.